Platelet genetic biomarker quantification: Comparison of fluorescent microspheres and PCR platforms

Summary

The platelet transcriptome has been extensively characterised using distinct genetic profiling platforms, with evolving evidence for differential expression patterns between healthy individuals and subject cohorts with various haematologic and cardiovascular disorders. Traditional technological platforms for platelet genetic biomarker quantification have limited applicability for clinical molecular diagnostics due to inherent complexities related to RNA isolation and analysis. We have previously established the feasibility of fluorescent microspheres as a simple and reproducible strategy for simultaneous quantification of platelet mRNAs from small volume of blood using intact platelets. We now extend these observations by formally comparing in a 50-member normal cohort the cross-platform behaviour of fluorescent microspheres to the currently accepted Q-PCR standard, using a clinically relevant 15-biomarker gene subset able to discriminate among normal and thrombocytosis cohorts. When compared to Q-PCR, genetic biomarker quantification using fluorescent microspheres demonstrated lower coefficients of variation for low-abundant transcripts, better linearity in serially diluted samples, and good overall between-platform consistency via the geometric mean regression. Neither platform demonstrated age or gender effects for any of the 15 biomarkers studied. Binding site saturation for highly abundant transcripts using fluorescent microspheres can be readily eliminated using an optimal platelet number corresponding to 0.3 ml of peripheral blood, additionally applicable to thrombocytopenic cohorts. These data provide a detailed cross-platform analysis using a relevant biomarker subset, further highlighting the applicability of fluorescent microspheres as potentially superior to Q-PCR for platelet mRNA diagnostics.

Keywords

Platelets - transcript profiling - fluorescent microspheres - mRNA - QuantiGene Plex 2.0 technology

• References

• 1 Stenberg PE, Hill RL. Platelets and megakaryocytes. In: Wintrobe’s Clinical Hematology. Philadelphia: Linnincott William Wilkins; 1999. pp. 615-660.
• 2 Newman P, Gorski J, White G, Gidwitz S, Cretney C, Aster R. Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 1988; 82: 739-743.
• 3 Levin J. The evolution of mammalian platelets. In: Platelets. Second ed:. Elsevier; 2007. pp. 3-23.
• 4 Fink L, Holschermann H, Kwapiszewska G. et al. Characterization of platelet-specific mRNA by real-time PCR after laser-assisted microdissection. Thromb Haemost 2003; 90: 749-756.
• 5 Rinder H, Schuster J, Rinder C. et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91: 1288-1294.
• 6 Gnatenko DV, Perrotta PL, Bahou WF. Proteomic approaches to dissect platelet function: one-half of the story. Blood 2006; 108: 3983-3991.
• 7 Gnatenko DV, Bahou WF. Recent advances in platelet transcriptomics. Transfus Med Hemother 2006; 33: 217-226.
• 8 Dittrich M, Birschmann I, Pfrang J. et al. Analysis of SAGE data in human platelets: features of the transcriptome in an anucleate cell. Thromb Haemost 2006; 95: 643-651.
• 9 Gnatenko DV, Dunn JJ, McCorkle SR. et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-2293.
• 10 Bugert P, Dugrillon A, Gunaydin A. et al. Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost 2003; 90: 738-748.
• 11 McRedmond JP, Park SD, Reilly DF. et al. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 2004; 03: 133-144.
• 12 Gnatenko DV, Cupit LD, Huang EC. et al. Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype. Thromb Haemost 2005; 94: 412-421.
• 13 Shim MH, Hoover A, Blake N. et al. Gene expression profile of primary human CD34+CD38lo cells differentiating along the megakaryocyte lineage. Exp Hematol 2004; 32: 638-648.
• 14 Tenedini E, Fagioli ME, Vianelli N. et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood 2004; 104: 3126-3135.
• 15 Rowley JW, Oler AJ, Tolley ND. et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011; 118: e101-111.
• 16 Cecchetti L, Tolley ND, Michetti N. et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
• 17 Kieffer N, Guichard J, Farcet JP. et al. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-195.
• 18 Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489-495.
• 19 Denis MM, Tolley ND, Bunting M. et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379-391.
• 20 Senzel L, Gnatenko D, Bahou W. Platelet transcriptome and cardiovascular disease. Future Cardiol 2007; 03: 391-398.
• 21 Gnatenko DV, Zhu W, Bahou WF. Multiplexed genetic profiling of human blood platelets using fluorescent microspheres. Thromb Haemost 2008; 100: 929-936.
• 22 Gnatenko DV, Zhu W, Xu X. et al. Class prediction models of thrombocytosis using genetic biomarkers. Blood 2010; 115: 7-14.
• 23 Kriegova E, Arakelyan A, Fillerova R. et al. PSMB2 and RPL32 are suitable denominators to normalize gene expression profiles in bronchoalveolar cells. BMC Mol Biol 2008; 09: 69.
• 24 de Jonge HJM, Fehrmann RSN, de Bont ESJM. et al. Evidence Based Selection of Housekeeping Genes. PloS one 2007; 02: e898.
• 25 Ludbrook J. Linear regression analysis for comparing two measurers or methods of measurement: But which regression?. Clin Exp Pharmacol Physiol 2010; 37: 692-699.
• 26 Linnet K. Evaluation of regression procedures for methods comparison studies. Clin Chem 1993; 39: 424-432.
• 27 Canales RD, Luo Y, Willey JC. et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nature Biotechnol 2006; 24: 1115-1122.
• 28 Murphy S, Peterson P, Iland H. et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Sem Hematol 1997; 34: 29-39.
• 29 Freedman JE, Larson MG, Tanriverdi K. et al. Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study. Circulation 2010; 122: 119-129.
• 30 Shipp MA, Ross KN, Tamayo P. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 08: 68-74.
• 31 Bhattacharjee A, Richards WG, Staunton J. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-13795.
• 32 Singh D, Febbo PG, Ross K. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 01: 203-209.
• 33 Ferrando AA, Neuberg DS, Staunton J. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 01: 75-87.
• 34 Ramaswamy S, Ross KN, Lander ES. et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
• 35 Kralovics R, Passamonti F, Buser AS. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
• 36 Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005; 42: 230-238.
• 37 Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer 2012 Epub ahead of print.